Cardiac arrest - Pharmacology and Temperature Management

Pharmacological Management of Cardiac Arrest Introduction Cardiac arrest is a life-threatening emergency requiring both mechanical interventions (such as cardiopulmonary resuscitation and defibrillation) and pharmacological support. The medications used during cardiac arrest are designed to restore heart rhythm, improve blood flow to vital organs, and correct the underlying physiological disturbances that caused the arrest. Understanding which medications to use, when to use them, and their expected outcomes is essential for emergency care providers. The key principle underlying cardiac arrest medication therapy is that while these drugs can improve the chances of return of spontaneous circulation (ROSC)—meaning the heart starts beating again—they often do not improve the patient's neurological outcomes or survival to hospital discharge. This distinction is critical because patients may regain a heartbeat but remain in a comatose state. Catecholamines: Epinephrine Epinephrine is the primary medication given during cardiac arrest and serves as the foundation of pharmacological resuscitation. It works by stimulating alpha-1 receptors on blood vessels, which causes vasoconstriction and increases blood pressure. During cardiac arrest, this effect is particularly important because it redirects blood flow toward the coronary arteries and brain—the two organs most vulnerable to the lack of circulation. Dosing and Timing In adults, epinephrine is given at a dose of 1 mg intravenously after the initial cycle of cardiopulmonary resuscitation (CPR) and defibrillation attempts. After this first dose, additional 1 mg doses are administered every 3–5 minutes for as long as resuscitation efforts continue. This interval of 3–5 minutes aligns with the standard CPR cycle length, allowing medication administration to be integrated seamlessly into the resuscitation protocol. An important note: doses higher than 1 mg are not recommended for routine use in cardiac arrest. While higher doses might seem beneficial, studies have shown they do not improve outcomes and may potentially be harmful. Application to Different Rhythms Epinephrine is used in all types of cardiac arrest rhythms: In shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia), epinephrine is given after the initial defibrillation attempt and repeated every 3–5 minutes In non-shockable rhythms (asystole and pulseless electrical activity), epinephrine is the primary medication given every 3–5 minutes, with the goal of converting the rhythm into a shockable rhythm that can then be treated with defibrillation Limitations of Epinephrine A crucial point that often surprises students: epinephrine improves overall survival (the return of spontaneous circulation) but does not increase neurologically intact survival. This means that while epinephrine may restart the heart, patients who receive it during arrest are not more likely to wake up with intact brain function. The neurological outcome appears to depend more on the underlying cause of arrest and how quickly blood flow is restored through CPR rather than on epinephrine itself. Anti-arrhythmic Medications When the heart is in a chaotic arrhythmia (such as ventricular fibrillation) or a dangerously fast rhythm, anti-arrhythmic medications help stabilize the electrical activity of the heart. Two main anti-arrhythmics are used in cardiac arrest. Amiodarone Amiodarone is a Class III anti-arrhythmic and is the preferred medication for treating ventricular fibrillation, pulseless ventricular tachycardia, and wide-complex tachycardias. The dosing protocol is straightforward: First dose: 300 mg as a rapid intravenous bolus Second dose: 600 mg as a rapid intravenous bolus if needed (given after ROSC or if the first dose did not convert the rhythm) Amiodarone is given earlier in the resuscitation sequence than epinephrine in shockable rhythms—typically after defibrillation attempts if the rhythm does not convert initially. Lidocaine Lidocaine is a Class IB anti-arrhythmic used as an alternative when amiodarone is unavailable or contraindicated. It is less preferred than amiodarone due to limited evidence of benefit. Important Caveat: Survival Outcomes A critical finding that challenges intuition: neither amiodarone nor lidocaine improves survival to hospital discharge. However, both medications do increase the rate of return of spontaneous circulation and admission to the hospital. This means these drugs help get the heart beating again temporarily, but patients are not more likely to ultimately survive their hospitalization or maintain neurological function. This underscores the importance of other interventions—particularly early CPR, prompt defibrillation, and post-resuscitation care—in determining long-term outcomes. Medications for Specific Disturbances Several cardiac arrest medications are indicated for specific metabolic or toxic conditions rather than as routine agents. Sodium Bicarbonate Sodium bicarbonate is used to correct severe metabolic acidosis or severe hyperkalemia (elevated potassium) when these conditions are known to be contributing to cardiac arrest. The mechanism is straightforward: severe acidosis depresses cardiac function and responsiveness to other medications, and hyperkalemia causes dangerous changes in the heart's electrical properties. The key clinical point: routine use of bicarbonate is not recommended during cardiac arrest unless there is clear evidence of severe acidosis or hyperkalemia. Giving bicarbonate without evidence of these conditions may actually worsen the acidosis paradoxically and does not improve outcomes. Calcium Chloride Calcium chloride serves as both an inotrope (increases cardiac contractility) and vasopressor (increases blood pressure). It is indicated for two specific conditions: Hyperkalemia (elevated potassium)—calcium stabilizes the cardiac membrane and protects against dangerous arrhythmias Calcium-channel blocker toxicity—calcium directly antagonizes the effects of overdosed calcium-channel blocker medications However, calcium is not given routinely during cardiac arrest in the absence of these specific conditions. Studies show that routine calcium administration does not improve outcomes and may actually worsen neurologic recovery in survivors, possibly by increasing cellular calcium overload and triggering cascades of cell death. Magnesium Sulfate Magnesium sulfate has a specific and important indication: treating torsades de pointes, a dangerous polymorphic ventricular tachycardia that typically occurs in the setting of a prolonged QT interval. The dose is 2 g given intravenously (or can be given orally in some settings). Like other cardiac arrest medications, magnesium is not given routinely without a specific indication. Its use should be reserved for situations where torsades de pointes is diagnosed or strongly suspected. Medications for Bradycardia: Atropine Atropine is an anticholinergic medication that increases heart rate by blocking the vagus nerve's inhibitory effects on the heart. It is used to treat symptomatic bradycardia (slow heart rate that is causing symptoms such as hypotension, altered mental status, or chest discomfort). Dosing For symptomatic bradycardia: Initial dose: 1 mg intravenously Additional doses: 1 mg may be repeated every 3–5 minutes Maximum total dose: 3 mg This dosing pattern is different from cardiac arrest algorithms because the patient has a perfusing rhythm and is not in arrest. Important Change in Guidelines A significant update to modern cardiac arrest guidelines: atropine is no longer recommended for pulseless electrical activity or asystole (non-shockable rhythms). This represents a departure from older resuscitation protocols. The rationale is that evidence does not support atropine's use in these conditions—it does not improve ROSC or survival, and its use does not result in conversion to shockable rhythms. Therefore, epinephrine remains the primary medication for non-shockable rhythms. <extrainfo> Medications for Specific Toxins and Conditions Naloxone Naloxone is an opioid receptor antagonist that reverses opioid overdose. It may be administered when cardiac arrest is suspected to result from opioid overdose. However, evidence of benefit is limited, and the practical reality is that resuscitative efforts (CPR) are the primary intervention. Naloxone should not delay or replace standard resuscitation. Thrombolytics Intravenous thrombolytic therapy (clot-dissolving medication) may be beneficial in cardiac arrest caused by a confirmed pulmonary embolism (blood clot in the lungs). This is one of the few conditions where a medication beyond the standard resuscitation drugs may offer a specific survival benefit. However, thrombolytics must only be given when PE is confirmed or strongly suspected, as they carry significant bleeding risks. Intravenous Lipid Emulsion Intravenous lipid emulsion is a specialized rescue therapy that can be considered for cardiac arrest due to local anesthetic toxicity (overdose of medications like propofol or lidocaine used for anesthesia). This is a rare but important indication for providers who work in anesthesia settings. Vasopressin and Methylprednisolone Vasopressin is a hormone that causes vasoconstriction. When used alone during cardiac arrest, vasopressin does not improve outcomes compared with epinephrine. However, the combination of epinephrine, vasopressin, and methylprednisolone (a corticosteroid) may improve survival after cardiac arrest in some patients. This combination approach is not standard in all guidelines and may be considered in specific situations, though its routine use is not universally recommended. </extrainfo> Targeted Temperature Management Rationale and Goals Targeted temperature management (also called therapeutic hypothermia) is a cornerstone of post-resuscitation care designed to improve neurological recovery after cardiac arrest. The principle is that cooling the body reduces the metabolic rate and decreases the chemical reactions that lead to brain cell death during the period after blood flow is restored. The target is to cool adult cardiac arrest patients to 32–36°C (90–97°F) for 24 hours. After the cooling period, patients are gradually rewarmed over 12–24 hours rather than being allowed to warm passively, as sudden rewarming can trigger additional injury. Cooling Methods Targeted temperature management typically uses practical surface-cooling techniques: Ice packs or cold-water circulating pads applied directly to the patient's body are the most common approach Infusion of cold saline intravenously can also lower core temperature These methods can be initiated in various settings, from the ambulance to the emergency department to the intensive care unit. Evidence of Benefit Systematic reviews have demonstrated that targeted temperature management improves neurological outcomes after out-of-hospital cardiac arrest. This is one of the few interventions in post-resuscitation care with solid evidence of benefit beyond simply restoring heart rhythm. However, an important caution: pre-hospital initiation of targeted temperature management (starting cooling before the patient reaches the hospital) may increase the risk of adverse outcomes, including higher rates of re-arrest. This suggests that the physiologic stress of rapid cooling in the pre-hospital environment may outweigh benefits in some cases. Current guidelines generally recommend initiating targeted temperature management in-hospital rather than pre-hospital. Complications Like any intervention, targeted temperature management carries risks. The therapy can cause adverse neurologic effects in survivors, and careful monitoring is required. The mechanisms of these effects are not completely understood but may relate to the stress of rapid temperature changes or other physiologic perturbations induced by the cooling process. Patients undergoing this therapy require intensive monitoring in an ICU setting. Summary of Key Principles When studying pharmacological management of cardiac arrest, keep these crucial points in mind: Most cardiac arrest medications improve ROSC but not neurological outcomes—this is perhaps the most important conceptual point to understand Epinephrine remains the foundation of cardiac arrest pharmacotherapy Use specific medications for specific conditions—avoid routine administration of agents like calcium or bicarbonate without clear indications Post-resuscitation care matters as much as resuscitation itself—targeted temperature management is evidence-based and should be part of the plan for all cardiac arrest survivors Timing and integration with non-pharmacological interventions (CPR, defibrillation) are as important as the medications themselves